MedTrace Logo

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

NCT06113328 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 169

Last updated 2026-03-17

Study results available
· View outcomes & findings →

Summary

Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on their face compared to people who take placebo.

Conditions

  • Non-segmental Vitiligo

Interventions

BIOLOGICAL

MK-6194

MK-6194 administered subcutaneously (SC)

DRUG

Placebo

Placebo comparator to MK-6194 administered SC

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-27
Primary Completion
2025-03-20
Completion
2025-07-30
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Canada
  • Chile
  • Colombia
  • France
  • Germany
  • Israel
  • Japan
  • Mexico
  • Netherlands
  • South Korea
  • Spain
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06113328 on ClinicalTrials.gov